One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1093/annonc/mdz248.003
Copy DOI Journal: Annals of Oncology |  Publication Date: Oct 1, 2019 |
 Citations: 64 |  License type: elsevier-specific: oa user license |
Affiliation: Sarah Cannon Research Institute, The University of Texas Health Science Center at Houston, Tallaght University Hospital, Geelong Hospital, Clovis Oncology (United Kingdom), Institute Curie, Clovis Oncology (United States), Cabrini Hospital, Memorial Sloan Kettering Cancer Center, University of Liège, University of Chicago, Moffitt Cancer Center846PD - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
